Avian influenza is an important zoonotic disease that has become endemic in Southeast Asia and in the case of highly pathogenic H5N1 has caused significant human mortality and morbidity. Avian influenza virus (AIV) infections may be asymptomatic or present as mild conjunctivitis in humans; however, H5N1 infections may present as severe pneumonia progressing to acute respiratory disease syndrome, multiorgan dysfunction syndrome and death. Since 2003, there have been a total of 436 cases and 262 deaths due to H5N1 infections. The number of cases has decreased steadily since 2006; however, the emergence of multiple genetically distinct sublineages of H5N1 has continued. These emerging sublineages display varying levels of drug resistance and in some cases an increased preference for binding to human α2,6-linked sialic acid cellular receptors. Though H5N1 has not shown efficient transmissibility between humans, the rapid evolution of the virus presents a concern for the emergence of a virus with this capability. Here we review the epidemiology, host range, clinical features, prophylaxis and treatment options, and preventative measures recommended for AIV with an emphasis on H5N1.

Keywords:
Epidemiology, Avian influenza virus, Clades, Clinical signs, H5N1, Vaccine
This content is only available via PDF.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.